3 Magnificent Dividend Growth Stocks With Yields Above 5% to Buy Now and Hold at Least a Decade
There are many ways to make money on Wall Street, but some methods are a lot more reliable than others. Whether you're ...
Too Old to Operate2d
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Talazoparib and enzalutamide tied to improved overall survival in metastatic prostate cancer
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price ...
Why Pfizer's Stock Price Isn't Reflecting Its True Value
Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...
appliedclinicaltrialsonline4d
Five-Year POETYK PSO Trial Results Show Sustained Efficacy, Safety with Sotyktu for Moderate-to-Severe Plaque Psoriasis
Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...
Pharmabiz7d
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoC
Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer
Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...
appliedclinicaltrialsonline7d
Updated TALAPRO-2 Trial Data Confirms Talzenna Plus Xtandi Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) ...
The American Journal of Managed Care7d
TALAPRO-2 Overall Survival Data Suggest New Standard of Care in mCRPC, Regardless of Genomic Status
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
Medscape7d
Talazoparib Combo Prolongs Survival in Metastatic Prostate Cancer
Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...